Benchmark Financial Wealth Advisors LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Benchmark Financial Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 1.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 871 shares of the company’s stock after buying an additional 16 shares during the period. Benchmark Financial Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $771,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Radnor Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $10,907,000. Callahan Advisors LLC raised its stake in shares of Eli Lilly and Company by 2.1% in the 3rd quarter. Callahan Advisors LLC now owns 14,881 shares of the company’s stock valued at $13,184,000 after purchasing an additional 301 shares in the last quarter. Leslie Global Wealth LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $354,000. Invictus Private Wealth LLC raised its stake in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. Invictus Private Wealth LLC now owns 421 shares of the company’s stock valued at $373,000 after purchasing an additional 16 shares in the last quarter. Finally, Wisconsin Capital Management LLC raised its stake in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. Wisconsin Capital Management LLC now owns 7,439 shares of the company’s stock valued at $6,591,000 after purchasing an additional 42 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.1 %

Eli Lilly and Company stock opened at $806.60 on Wednesday. The stock has a market capitalization of $765.72 billion, a PE ratio of 87.20, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a 50 day simple moving average of $905.20 and a 200-day simple moving average of $867.96.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 13.23 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.64%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Barclays dropped their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.